| 5.51 0.77 (16.24%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.88 | 1-year : | 8.26 |
| Resists | First : | 5.89 | Second : | 7.07 |
| Pivot price | 4.74  |
|||
| Supports | First : | 3.98 | Second : | 3.31 |
| MAs | MA(5) : | 4.76 |
MA(20) : | 5.08 |
| MA(100) : | 6.05 |
MA(250) : | 7.79 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 51.1 |
D(3) : | 35.6 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 13.68 | Low : | 3.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALGS ] has closed below upper band by 14.3%. Bollinger Bands are 19.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.61 - 5.64 | 5.64 - 5.67 |
| Low: | 4.13 - 4.15 | 4.15 - 4.17 |
| Close: | 5.46 - 5.51 | 5.51 - 5.55 |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Thu, 06 Aug 2026
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results - Investing News Network
Thu, 06 Aug 2026
Aligos Therapeutics, Inc. (ALGS) Stock Price, News, Quote & History - Yahoo Finance
Thu, 06 Aug 2026
Aligos Therapeutics reports Q2 2026: $27.8M licensing revenue, $1.5M net loss, $30.4M cash - TradingView
Thu, 30 Jul 2026
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
Thu, 30 Jul 2026
Aligos Therapeutics to report results before markets open Aug. 6 - Stock Titan
Mon, 27 Jul 2026
ALGS|Aligos Therapeutics Inc|Price:4.260|Chg%:-0.060 - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 55 (%) |
| Shares Short | 521 (K) |
| Shares Short P.Month | 612 (K) |
| EPS | -9.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.13 |
| Profit Margin | 0 % |
| Operating Margin | -951.6 % |
| Return on Assets (ttm) | -55.6 % |
| Return on Equity (ttm) | -121.9 % |
| Qtrly Rev. Growth | 810 % |
| Gross Profit (p.s.) | -12.04 |
| Sales Per Share | 0.87 |
| EBITDA (p.s.) | -17.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 0 |
| Price to Book value | 1.07 |
| Price to Sales | 6.3 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|